Clinical Trials Logo

B-Cell Lymphoma clinical trials

View clinical trials related to B-Cell Lymphoma.

Filter by:

NCT ID: NCT04213469 Completed - B-cell Lymphoma Clinical Trials

PD1-CD19-CART in Patients With r/r B-cell Lymphoma

Start date: March 13, 2020
Phase: N/A
Study type: Interventional

This is an open label, single-site, dose-escalation study in up to 25 participants with relapse/refractory B-NHL. This study aims to evaluate the safety and efficacy of the treatment with PD1-CD19-CART.

NCT ID: NCT04156243 Recruiting - B Cell Lymphoma Clinical Trials

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

Start date: February 1, 2018
Phase: Early Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.

NCT ID: NCT04156178 Recruiting - B Cell Lymphoma Clinical Trials

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

Start date: August 1, 2018
Phase: Early Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD20-CD19 cCAR in patients with relapsed and/or refractory B cell malignancies.

NCT ID: NCT04148430 Active, not recruiting - B-Cell Lymphoma Clinical Trials

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

Start date: October 30, 2019
Phase: Phase 2
Study type: Interventional

This study is being done to see if the investigational drug, anakinra, prevent or reverse the severe side effects caused by CAR-T cell therapy.

NCT ID: NCT04088864 Active, not recruiting - Lymphoma Clinical Trials

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Start date: January 10, 2020
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from pediatric and young adult subjects with relapsed/refractory B-cell malignancies (leukemia and lymphoma). Another purpose of this study is to test the safety and cancer killing ability of a cell therapy against a new cancer target (CD22).

NCT ID: NCT04045028 Terminated - Multiple Myeloma Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Start date: July 22, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with atezolizumab and/or daratumumab or rituximab in participants with relapsed or refractory (R/R) multiple myeloma (MM) or R/R non-Hodgkin lymphoma (NHL).

NCT ID: NCT04036019 Completed - B Cell Lymphoma Clinical Trials

A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

Start date: August 20, 2019
Phase: Phase 1
Study type: Interventional

This is a single-center, non-randomized clinical study to evaluate the safety and efficacy of C-CAR066 in treatment of r/r B cell lymphoma who received CD19 CAR-T therapy.

NCT ID: NCT04035434 Active, not recruiting - Clinical trials for Non-Hodgkin Lymphoma

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

Start date: July 22, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.

NCT ID: NCT04023071 Terminated - Clinical trials for Acute Myelogenous Leukemia

FT516 in Subjects With Advanced Hematologic Malignancies

Start date: October 4, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study includes three stages: dose escalation, safety confirmation, and dose expansion.

NCT ID: NCT04018248 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)

Start date: April 21, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase I-II, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia, Phase Ib). The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose for expansion (RP2D) of BR101801 in subjects with relapsed/refractory B cell lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), and peripheral T cell lymphoma (PTCL). The Phase Ib (dose expansion) part of the study is designed to assess tumor response and safety in specific advanced relapsed/refractory Peripheral T-cell lymphoma(PTCL) at a dose of BR101801 identified in Phase Ia. Once the RP2D has been determined in Phase Ia (dose escalation), Phase Ib (dose expansion) will commence.